MK 3866
Alternative Names: MK-3866Latest Information Update: 28 Oct 2020
At a glance
- Originator Merck Sharp & Dohme
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Bacterial-infections in USA (IV, Infusion)
- 29 Jan 2019 Merck Sharp & Dohme terminates a phase I trial in Healthy volunteers in USA due to business and programme changes (NCT03295266)
- 24 Apr 2018 Merck suspended a phase I trial in Merck due to further evaluations of ongoing animal safety investigations (NCT03295266)